Nevertheless, in some of the ongoing clinical trials, anti-CD19 CAR-T cell products are also being examined for patients with other autoimmune diseases, such as immune thrombocytopenia, primary biliary cholangitis, IgG4-related disease, neuromyelitis optica, multiple sclerosis, and myasthenia gravis, given the common pathophysiological mechanism between these clinical entities. The gene discussed is CD19; the disease is autoimmune disease.